Researchers provide new insights into SARS-CoV-2 lung pathology
The new study shows how SARS-CoV-2 significantly remodels cellular processes in just an hour and identifies potential drug targets and therapeutics for COVID-19.
List view / Grid view
The new study shows how SARS-CoV-2 significantly remodels cellular processes in just an hour and identifies potential drug targets and therapeutics for COVID-19.
Researchers report that their LEAPS COV-19 peptides significantly improved survival in a murine model of COVID-19.
According to new research, the protein ALDH4A1 is a possible therapeutic target and diagnostic biomarker for cardiovascular disease.
Researchers at Ingenza and the University of Plymouth are using a machine learning and high‑throughput screening approach to discover novel antimicrobial therapies. In this article, Nikki Withers spoke to one of the researchers, Jack Kay, to hear about the current threat posed by antimicrobial resistance and how he hopes their…
The novel probes, known as positive controls, could make it easier to validate rapid, point-of-care diagnostic tests for COVID-19 across the globe.
According to researchers, the more small tau protein variants expressed by neurons, the slower neurofibrillary tangles form.
An artificial intelligence (AI) system called AlphaFold has been developed to effectively predict protein structures and folding.
Professor Laurence D Hurst explains why understanding the nucleotide mutations in viruses, including SARS-CoV-2, can have significant implications for vaccine design.
By combining machine learning and T-cell engineering researchers were able to develop cell therapies that can selectively and effectively target and destroy solid tumours.
Researchers from Massachusetts General Hospital have studied several thousand circulating proteins within the plasma proteome of symptomatic COVID-19 patients and acutely ill non-COVID-19 controls. Nikki Withers discussed their findings and implications of the study with one of the lead authors, Dr Mike Filbin.
Researchers reveal how two genetic variations may contribute to COVID-19 disease severity and suggest the product of one, the CD209 antigen, may be a potential drug target.
Researchers have shown that 70 percent of Alzheimer’s patients have high levels of proteins associated with dysfunction in the endosomal trafficking system in their spinal fluid.
A study in healthcare workers has shown that antibodies from COVID-19 infection protect individuals from reinfection for at least six months.
Rodent studies show that using antibodies with different targets and modes of action in combination is more effective at preventing and treating COVID-19.
Using atomistic simulations, a team has demonstrated how coronavirus Spike proteins move and vibrate to let the virus through cell walls.